Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers

2022 ◽  
Author(s):  
Huseyin Tugsan Balli ◽  
Kairgeldy Aikimbaev ◽  
Isa Burak Guney ◽  
Ferhat Can Piskin ◽  
Begul Yagci-Kupeli ◽  
...  
Keyword(s):  
Systemic Chemotherapy ◽  
Yttrium 90

scholarly journals Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Vlasios S. Sotirchos ◽  
Elena N. Petre ◽  
Karen T. Brown ◽  
Lynn A. Brody ◽  
Michael I. D’Angelica ◽  
...  
Keyword(s):  
Biliary Obstruction ◽  
Colorectal Liver Metastases ◽  
Systemic Chemotherapy ◽  
Hepatic Metastases ◽  
Biliary Stent ◽  
Hepatic Arterial Chemotherapy ◽  
Heavily Pretreated ◽  
History Of ◽  
Recurrent Colon Cancer ◽  
Yttrium 90

We report a case of safe and successful yttrium-90 resin microsphere radioembolization in a patient with a long history of multiple recurrent colon cancer hepatic metastases progressing after hepatic resections, hepatic arterial chemotherapy, and multiple regimens of systemic chemotherapy. One month prior to radioembolization, a biliary stent was placed above the level of the ampulla to relieve tumor-related biliary obstruction and normalize bilirubin levels.

scholarly journals Metastatic appendiceal cancer treated with Yttrium 90 radioembolization and systemic chemotherapy: A case report

2019 ◽  
Vol 11 (13) ◽  
pp. 116-125 ◽  
Author(s):  
Ambarish P Bhat ◽  
Philip A Schuchardt ◽  
Roopa Bhat ◽  
Ryan M Davis ◽  
Sindhu Singh
Keyword(s):  
Case Report ◽  
Systemic Chemotherapy ◽  
Appendiceal Cancer ◽  
Yttrium 90

Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 625-625
Author(s):  
Constantinos T Sofocleous ◽  
Nancy E. Kemeny ◽  
Neeta Pandit-Taskar ◽  
Kinh Gian Do ◽  
Lynn A Brody ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Post Treatment ◽  
The Body ◽  
Oncologic Outcomes ◽  
The Third ◽  
Colon Cancer Liver Metastases ◽  
Grade 3 ◽  
Yttrium 90

625 Background: Prospective evaluation of the safety of Selective Interval Radiation Therapy (SIRT) using yttrium 90 microspheres (Y90) in patients with colon cancer liver metastases (CLM) who failed hepatic arterial (pump) and systemic chemotherapy. Methods: This prospective single center study, assessed the safety, dose limiting toxicities (DLT) and the maximum tolerated dose (MTD) of Y90 in a selected, heavily pretreated population. Upon IRB and FDA approval individualized Y90 doses were calculated according to a volumetric method and the body surface area (BSA) method as instructed by the company. SIRT treatment was administered in three escalating dose levels (cohorts): the first cohort received 70%, the second 85%, and the third 100% of the calculated dose. All patients received chemotherapy as deemed by the patients' medical oncologist post SIRT treatment. DLT was defined as new, post treatment, grade 3 toxicities, and evaluated according to the NCI Common Toxicity Criteria (NCI-CTC) 3.0. Response to treatment was evaluated by imaging (using a combination of WHO, RECIST, modified RECIST and SUV changes) and CEA levels. Kaplan Meier methodology was employed to calculate Progression Free (PFS) and Overall (OS) Survival. Results: From September 2009-2011, 19 patients received Y90. Common complaints post treatments were: grade 1-2 fatigue and grade 1 fever, which are known side effects of SIRT. No DLTs were observed. Grade 3 hyperbilirubinemia was recorded for two patients and was attributed to progressive disease; one patient in the third cohort suffered grade 3 nausea and pain. Twelve patients (70.6%) responded (defined as stable disease or better) while five (29.4%) progressed-this was based on evaluations from initial post treatment imaging. Two patients’ imaging is pending. Median PFS and OS were 6 [95%CI: 3.2-9.7] and 16 [95%CI: 5.8-17.6] months respectively. Conclusions: It is safe to administer the entire dose of Y90 in patients with CLM who progressed despite prior pump and systemic chemotherapy. Oncologic outcomes are promising.

Phase II study of first-line radioembolization with yttrium-90 glass microspheres for intrahepatic cholangiocarcinoma.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 482-482 ◽  
Author(s):  
Ravi Shridhar ◽  
Jessica M. Frakes ◽  
Binglin Yue ◽  
Richard D. Kim ◽  
Gregory M. Springett ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Phase Ii ◽  
Intrahepatic Cholangiocarcinoma ◽  
Systemic Chemotherapy ◽  
Phase Ii Study ◽  
Performance Status ◽  
Glass Microspheres ◽  
First Line ◽  
Grade 3 ◽  
Yttrium 90

482 Background: The standard of care for unresectable intrahepatic cholangiocarcinoma (ICC) is systemic chemotherapy. The role of liver directed therapy for ICC is controversial given the lack of level I data. We conducted a phase II study to determine the safety and effectiveness of first-line liver directed therapy with radioembolization with yttrium-90 (Y90) glass microspheres for ICC. Methods: Eligible patients were enrolled on an IRB-approved phase II study (NCT01253148). Patients were included if they had no evidence of extrahepatic metastases, Childs-Pugh A, without main portal vein thrombus, bilirubin < 2 mg/dL, ECOG performance status of 0-2, and no prior chemotherapy, liver embolization, or radiation therapy for ICC. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and toxicity. Results: Twenty-five patients were enrolled between 2010 and 2013 with a median followup of 13 months (9-20 months). The median age was 76 years. Twenty patients came off study due to progression or death. The overall response rate was 56%. Median PFS was 6 months (95% CI: 4-12 months). This was likely due to tumors appearing larger after treatment due to tumor inflammation despite a decrease in CA19-9 levels. Univariate (UVA) and multivariate analysis (MVA) failed to identify any prognostic factors associated with PFS. Despite the low median PFS, median OS was 22 months (95% CI: 10 months to upper limit not reached). However, UVA and MVA failed to identify and prognostic factors for OS. Treatment was well tolerated with no reported grade 3 gastrointestinal or general disorder toxicities. Grade 3 ALT, AST, and alkaline phosphatase increase were reported in 4%, 4%, and 8%, respectively. Grade 4 hyperbilirubinemia and thrombocytopenia were reported in 4% and 4%, respectively. There were 2 patient who developed sepsis one patient who died within 30 days of treatment. Conclusions: First-line liver directed therapy with radioembolization with Y90 glass microspheres is a safe and effective treatment for ICC. Further prospective clinical trials are needed to identify the proper sequencing of liver directed therapy and systemic chemotherapy. Clinical trial information: NCT01253148.

Sign in / Sign up

Export Citation Format

Share Document